Développement de nouveaux agents de contraste vectorisés

!"#$%&''$($)*+,$+)&-#$.-/+.0$)*1+,$+2&)*3.1*$+#$2*&341"1+
,$15)"1+.-+,4.0)&152+'.3+678+,$+%.+(.%.,4$+,9:%;<$4($3+
Emilie&ANSCIAUX,&C.&Burtea,&L.&Vander&Elst,&S.&Laurent,&R.N.&Muller&
Service&de&Chimie&Générale,&Organique&et&Biomédicale&–&Université&de&Mons,&Belgique&
Financement&:&Bourse&Umons&
=&)*$/*$+124$)5>?-$+$*+'3&@%"(.5?-$+
8.%.,4$+,9:%;<$4($3++A+)$-3&,"0")"3.5#$+$*+4)2-3.@%$+
++
Qualités&requises:&
B C.-*$+ .D)4*"+ $*+ 1'"24>24*"+
$)#$31+%.+24@%$+
B =%.43.)2$+'%.1(.5?-$+E.4@%$+
B :-2-)+$F$*+2G*&*&/4?-$+
B =.'.@%$+,$+'.11$3+%.+HCI+
=&)2%-14&)1+$*+'$31'$25#$1+
=&)2%-14&)1+
J$31'$25#$1+
K@*$)5&)+,$1+?-.%4*"1+3$?-41$1+'&-3+-)+@&)+.0$)*+,$+2&)*3.1*$+#$2*&341"+
L"34>2.5&)+,-+'.11.0$+,$+%.+HCI+1-3+2-%*-3$+2$%%-%.43$+
6(.0$34$+1-3+1&-341+*3.)10")4?-$1+:%;<$4($3+:JJMJNO+
=&('"*$)2$1+
N24$)5>?-$1+
H4&%&04$+(&%"2-%.43$+P2-%*-3$+2$%%-%.43$Q+*&/424*"Q+.D)4*"R+
I/'"34($)*.5&)1+1-3+%$+'$5*+.)4(.%+P1&-341R+
C41*&%&04$M6((-)&<41*&2<4(4$+
78S+$*+678+
T3.)1#$31.%$1+
6)*$3#$)5&)+$)+2&)E"3$)2$1M2&%%&?-$1+
:-*&)&(4$Q+.,.'*.@4%4*"Q+0$15&)+,$+'3&U$*+
7",.25&)+,9.352%$1+$*+,$+3.''&3*1+,9.25#4*"1+
I)2.,3$($)*+,9"*-,4.)*1+$*+'341$+,$+3$1'&)1.@4%4*"1+
J&%G"*<G%V)$+0%G2&%+!+@&-2%4$3+
J$'5,$+!+03.''4)++
H4&(&%"2-%$+!+2%"+
:0$)*+,$+2&)*3.1*$!+1&%,.*+
6%%-1*3.5&)+,9-)+.0$)*+,$+2&)*3.1*$+#$2*&341"+
=&('.3.41&)+ 2$3#$.-+ 1.4)+
P0.-2<$R+$*+2$3#$.-+W+-)+1*.,$+
.#.)2"+,9:%;<$4($3+P,3&4*$R+
8"*<&,&%&04$+$*+3"1-%*.*1+
X+'$'5,$1+,4F"3$)*1+JCKQ+JC6+$*+JO+!+*3&41+.0$)*1+,$+2&)*3.1*$+W+*$1*$3+
I#.%-.5&)1+,$1+2.3.2*"3415?-$1+,$1+.0$)*1+,$+2&)*3.1*$+
:D)4*"+$*+1'"24>24*"+$)#$31+%$1+'%.?-$1+
T$('1+,$+2432-%.5&)+,.)1+%$+1.)0+
H4&,41*34@-5&)+
:@1$)2$+,$+*&/424*"+1-3+2$%%-%$1+
J.11.0$+,$+%.+HCI+
=<&4/+ ,$+ %9.0$)*+ ,$+
2&)*3.1*$+ '3"1$)*.)*+
%$1+ ($4%%$-3$1+
2.3.2*"3415?-$1+
!4.0)&152+'3"2&2$+,$+%.+(.%.,4$+,9:%;<$4($3+
$*+ "#.%-.5&)+ ,$+ %9$D2.24*"+ ,$+ )&-#$.-/+
*3.4*$($)*1+*<"3.'$-5?-$1+
Y&3(.5&)+ ,$+ '%.?-$1+ .-+ )4#$.-+
,-+ 2$3#$.-+ ,$+ )&(@3$-1$1+
.))"$1+ .#.)*+ %9.''.345&)1+ ,$1+
1G('*Z($1[+
\ $ 1+ ' % . ? - $ 1+ 1 & ) *+
E&3("$1+ '.3+
%9.00%&("3.5&)+ ,-+
pep#de%amyloïde%beta%
8&3*+ ,$1+ )$-3&)$1Q+
.*3&'<4$+ ,-+ 2&3*$/+
2"3"@3.%+ $*+ '$3*$+ ,$1+
E&)25&)1+2&0)45#$1[+
L41-.%41.5&)+ ,$1+ '%.?-$1+
'.3+ 678Q+ #4.+ %9-5%41.5&)+
d’agents% de% contraste%
vectorisés.%+
!"*$25&)+ ,$+ '%.?-$1+
.(G%&],$1Q+'.3+678+
!"*$25&)+ ,$+ '%.?-$1+
.(G%&],$1+ 1-3+ 2&-'$+ ,$+
2$3#$.-+
Y&3(.5&)+ ,$+ '%.?-$1+
.(G%&],$1+ '.3+ 2%4#.0$+
,$+%.+'3&*"4)$+:JJ+'.3+
,$1+$);G($1+
J.11.0$+,$+%.+HCI+$*+.22-(-%.5&)+,.)1+%$+2$3#$.-Q+
^_+(4)-*$1+.'3V1+4)U$25&)+,9`NJ6KBJCK+
DiagnosJc&actuel&de&la&maladie:&
B T$1*1+2&0)45E1+!+'$-+'3"241+
B TIJ+!+4)U$25&)+,9-)+*3.2$-3+)-2%".43$+
678+ A+ 03.),$+ 3"1&%-5&)+ *$('&3$%%$+ $*+
1'.5.%$a+ '.1+ ,$+ 3$1*3425&)+ ?-.)*+ .-+
)&(@3$+,9$/.($)1Q+,"*$25&)+*3V1+'3"2&2$+